AstraZenica has agreed to pay $520m to settle allegations that it had marketed quetiapine for unapproved off-label uses. AstraZenica denied wrongdoing but signed the civil settlement with the US Department of Justice. AstraZenica was charged with the off-label advertising to doctors for aggression, Alzheimer’s, anger management, anxiety, ADHD, bipolar disease, dementia, depression, mood disorders, PTSD and sleeplessness.

BMJ 2010; 340: c2380